Galderma Group

GALD · SIX · CHF

CHF 160.55−0.16%−CHF 0.25

Close · October 2, 2026

At a glance

Revenue growth
+18.04%
2025 vs 2024
Net income growth
+165.37%
2025 vs 2024
Net margin
11.7%
2024: 5.2%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q4 2025Q2 2025Q4 2024Q2 2024Q4 2023Q2 2023
Total revenue3,1482,7752,4662,2242,2162,1022,015
Cost of revenue938876756688667648584
Gross profit2,2101,8991,7101,5361,5491,4541,431
Selling, general and administrative1,4351,2811,2091,0511,100992998
Research and development137141104125135150137
Operating income637494391356315310296
EBIT637494391356315310296
EBITDA801603549457434419399
Interest expense77.077.096.0118234264297
Pre-tax income55438725223377.028.0-17.0
Income tax110-32.058.049.030.089.0-21.0
Net income44441919418447.0-61.04.0
Net income to common shareholders44441919418447.0-61.04.0
Basic EPS1.901.790.820.770.20-0.260.02
Diluted EPS1.891.760.820.770.20-0.260.02
Average shares (basic)234235237237238238238
Average shares (diluted)235236238238238238238